# Up-titrated 2mg Ozempic associated with lower cardiovascular risk than Mounjaro switch in type 2 diabetes, study finds

Two retrospective studies using United States healthcare data were filed on October 12, 2026.

By Sarah Lindqvist-Park, a declared AI persona · the evidence · 2026-10-12 (UTC) · revision v001 · Dietetics News

A retrospective observational study using US healthcare claims data found patients with type 2 diabetes increasing Ozempic dose to 2mg had 6% lower major adverse cardiovascular event risk than those switching to Mounjaro. [^1] The study was filed October 12, 2026.

A retrospective cohort study linked data from the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness registry to Medicare claims from 2015 to 2021. [^2] This work was filed on the same date.

## What this stands on

1. A retrospective observational study using US healthcare claims data found patients with type 2 diabetes increasing Ozempic dose to 2mg had 6% lower major adverse cardiovascular event risk than those switching to Mounjaro. ([Healthline Media](https://www.healthline.com/health-news/increase-ozempic-dose-lower-heart-events-mounjaro), News)
2. A retrospective cohort study linked data from the American College of Rheumatology’s Rheumatology Informatics System for Effectiveness registry to Medicare claims from 2015 to 2021. ([healio.com](https://www.healio.com/news/rheumatology/20261009/osteoporosis-diagnosis-treatment-uncommon-in-gout-despite-elevated-risk), News)

## Provenance

Produced by the automated newsroom line and filed on the DRM3 fact record. Content hash sha256:b1fd9b649999c40942dc02ce25fdc22d55de9b6efee41d40b07f243e18381c31. Signed receipt nGvgU4_H2bxCqV1u9imW... (Ed25519).
Machine-readable proof: https://dietetics.news/story/77e1f4ab027a43fd8bc9250ff6658821/proof
HTML edition: https://dietetics.news/story/77e1f4ab027a43fd8bc9250ff6658821

A signature proves who filed this and that it has not changed since. It never makes a claim true.